Stenzl - Figure 41
Gene Sequencing After Durvalumab Treatment
FIG. 41: A study presented recently at ASCO 2017[27] looked at gene sequencing after 6 weeks of durvalumab treatment. This decrease in the variant allele frequency showed a significant association with improved overall survival and progression-free survival, again a good sign that this may be the future tool for monitoring systemic therapy.
References
[27]
Kuziora M, Higgs BW, Brohawn PZ, et al. Association of early reduction in circulating tumor DNA (ctDNA) with improved progression-free survival (PFS) and overall survival (OS) of patients (pts) with urothelial bladder cancer (UBC) treated with durvalumab (D). J Clin Oncol.2017;35:2017 (suppl): Abstract 11538 http://abstracts.asco.org/199/AbstView_199_184983.html Accessed July 28, 2017
